Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.40
AFFX's Cash to Debt is ranked higher than
50% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.05 vs. AFFX: 0.40 )
AFFX' s 10-Year Cash to Debt Range
Min: 0.15   Max: No Debt
Current: 0.4

Equity to Asset 0.56
AFFX's Equity to Asset is ranked higher than
63% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. AFFX: 0.56 )
AFFX' s 10-Year Equity to Asset Range
Min: 0.19   Max: 0.95
Current: 0.56

0.19
0.95
F-Score: 7
Z-Score: 1.23
M-Score: -2.96
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -3.80
AFFX's Operating margin (%) is ranked higher than
65% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.76 vs. AFFX: -3.80 )
AFFX' s 10-Year Operating margin (%) Range
Min: -139.9   Max: 17.26
Current: -3.8

-139.9
17.26
Net-margin (%) -4.94
AFFX's Net-margin (%) is ranked higher than
62% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. AFFX: -4.94 )
AFFX' s 10-Year Net-margin (%) Range
Min: -113.64   Max: 17.9
Current: -4.94

-113.64
17.9
ROE (%) -6.01
AFFX's ROE (%) is ranked higher than
64% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.60 vs. AFFX: -6.01 )
AFFX' s 10-Year ROE (%) Range
Min: -101.4   Max: 19.11
Current: -6.01

-101.4
19.11
ROA (%) -3.24
AFFX's ROA (%) is ranked higher than
65% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.69 vs. AFFX: -3.24 )
AFFX' s 10-Year ROA (%) Range
Min: -43.17   Max: 9.53
Current: -3.24

-43.17
9.53
ROC (Joel Greenblatt) (%) -17.17
AFFX's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.52 vs. AFFX: -17.17 )
AFFX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -166.29   Max: 70.53
Current: -17.17

-166.29
70.53
Revenue Growth (%) 0.80
AFFX's Revenue Growth (%) is ranked higher than
66% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. AFFX: 0.80 )
AFFX' s 10-Year Revenue Growth (%) Range
Min: -33.6   Max: 102.9
Current: 0.8

-33.6
102.9
EPS Growth (%) 15.30
AFFX's EPS Growth (%) is ranked higher than
87% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. AFFX: 15.30 )
AFFX' s 10-Year EPS Growth (%) Range
Min: -55.3   Max: 25.1
Current: 15.3

-55.3
25.1
» AFFX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

AFFX Guru Trades in Q3 2013

Paul Tudor Jones 47,200 sh (New)
Joel Greenblatt 268,084 sh (New)
Jim Simons 410,400 sh (New)
PRIMECAP Management 8,134,440 sh (+22.94%)
Chuck Royce 150,000 sh (unchged)
Murray Stahl 104,000 sh (unchged)
» More
Q4 2013

AFFX Guru Trades in Q4 2013

Jim Simons 1,032,500 sh (+151.58%)
PRIMECAP Management 10,666,640 sh (+31.13%)
Paul Tudor Jones 48,674 sh (+3.12%)
Murray Stahl 104,000 sh (unchged)
Chuck Royce 130,000 sh (-13.33%)
Joel Greenblatt 31,187 sh (-88.37%)
» More
Q1 2014

AFFX Guru Trades in Q1 2014

Joel Greenblatt 151,285 sh (+385.09%)
Paul Tudor Jones 56,400 sh (+15.87%)
PRIMECAP Management 10,690,540 sh (+0.22%)
Murray Stahl 104,000 sh (unchged)
Jim Simons 769,223 sh (-25.5%)
Chuck Royce 90,000 sh (-30.77%)
» More
Q2 2014

AFFX Guru Trades in Q2 2014

Murray Stahl 104,000 sh (unchged)
Chuck Royce 90,000 sh (unchged)
PRIMECAP Management 10,559,240 sh (-1.23%)
Joel Greenblatt 72,552 sh (-52.04%)
Paul Tudor Jones 20,400 sh (-63.83%)
Jim Simons 198,280 sh (-74.22%)
» More
» Details

Insider Trades

Latest Guru Trades with AFFX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Reduce -52.04%0.01%$6.37 - $9.419 $ 8.588%72552
Joel Greenblatt 2014-03-31 Add 385.09%0.01%$6.65 - $9.5 $ 8.586%151285
Joel Greenblatt 2013-12-31 Reduce -88.37%0.05%$6.35 - $8.85 $ 8.5812%31187
PRIMECAP Management 2013-12-31 Add 31.13%0.03%$6.35 - $8.85 $ 8.5812%10666640
Joel Greenblatt 2013-09-30 New Buy0.05%$3.78 - $6.3 $ 8.5866%268084
PRIMECAP Management 2013-09-30 Add 22.94%0.01%$3.78 - $6.3 $ 8.5866%8134440
Joel Greenblatt 2012-09-30 Sold Out 0.06%$3.61 - $4.7 $ 8.58106%0
Joel Greenblatt 2012-06-30 Reduce -50.63%0.07%$4.01 - $5.11 $ 8.5886%175755
PRIMECAP Management 2012-06-30 Add 149.79%0.03%$4.01 - $5.11 $ 8.5886%7025440
Joel Greenblatt 2012-03-31 Add 67.73%0.05%$4.11 - $5.21 $ 8.58105%356011
Joel Greenblatt 2011-12-31 Add 92.44%0.05%$3.7 - $5.83 $ 8.5880%212251
Joel Greenblatt 2011-09-30 New Buy0.09%$4.14 - $8 $ 8.5853%110294
Joel Greenblatt 2011-06-30 Sold Out 0.02%$5.01 - $7.85 $ 8.5836%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.30
AFFX's P/B is ranked higher than
78% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.38 vs. AFFX: 2.30 )
AFFX' s 10-Year P/B Range
Min: 0.24   Max: 12.23
Current: 2.3

0.24
12.23
P/S 1.80
AFFX's P/S is ranked higher than
78% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.42 vs. AFFX: 1.80 )
AFFX' s 10-Year P/S Range
Min: 0.38   Max: 11.22
Current: 1.8

0.38
11.22
PFCF 17.90
AFFX's PFCF is ranked higher than
86% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. AFFX: 17.90 )
AFFX' s 10-Year PFCF Range
Min: 1.89   Max: 1220.5
Current: 17.9

1.89
1220.5
Current Ratio 2.74
AFFX's Current Ratio is ranked higher than
69% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. AFFX: 2.74 )
AFFX' s 10-Year Current Ratio Range
Min: 1.52   Max: 23.52
Current: 2.74

1.52
23.52
Quick Ratio 1.83
AFFX's Quick Ratio is ranked higher than
60% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. AFFX: 1.83 )
AFFX' s 10-Year Quick Ratio Range
Min: 1.25   Max: 23.21
Current: 1.83

1.25
23.21

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.70
AFFX's Price/DCF (Projected) is ranked higher than
86% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. AFFX: 1.70 )
AFFX' s 10-Year Price/DCF (Projected) Range
Min: 0.42   Max: 219.36
Current: 1.7

0.42
219.36
Price/Median PS Value 1.00
AFFX's Price/Median PS Value is ranked higher than
70% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.20 vs. AFFX: 1.00 )
AFFX' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 37.7
Current: 1

0.3
37.7
Earnings Yield (Greenblatt) 0.70
AFFX's Earnings Yield (Greenblatt) is ranked lower than
64% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.90 vs. AFFX: 0.70 )
AFFX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 387
Current: 0.7

0.1
387
Forward Rate of Return (Yacktman) 1.78
AFFX's Forward Rate of Return (Yacktman) is ranked higher than
71% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.94 vs. AFFX: 1.78 )
AFFX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -18.5   Max: 2.3
Current: 1.78

-18.5
2.3

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:AFF.Germany
Affymetrix, Inc., was incorporated in California in 1992 and reincorporated in Delaware in 1998. The Company is a provider of life science tools and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. It sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. The Company's operations consist of two reportable segments, Affymetrix Core and eBioscience. Affymetrix Core is divided into three business units with each business unit having its own research, development and marketing groups to better serve customers and respond quickly to the market needs. In addition, the business units share common corporate services that provide capital, infrastructure and functional support, allowing them to focus on core technological strengths to compete and innovate in their markets. The three business units that form Affymetrix Core are: Expression, Genetic Analysis and Clinical Applications, and Life Science Reagents.Expression: This business unit develops and markets the Company's GeneChip gene expression products and services, and the QuantiGene line of low-to-mid-plex RNA measurement products; Genetic Analysis and Clinical Applications: This business unit develops and markets the Company's genotyping, such as the Axiom product line and arrays with clinical research applications, such as the CytoScan cytogenetics arrays; Life Science Reagents: This business unit develops and sells reagents, enzymes, purification kits and biochemicals used by life science researchers. eBioscience: This reportable segment specializes in the development, manufacturing, marketing and distribution of research tools in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Company markets and distributes its products directly to customers in North America, Japan and major European markets. The Company is facing competition as existing companies develop new or improved products, and as companies enter the market with new technologies, such as next-generation sequencing. In the highly multiplexed genotyping and gene expression markets, existing competitive technologies include DNA sequencing, which the Company does not offer and is offered by companies such as Illumina, Inc., Life Technologies Corporation and Pacific Biosciences of California, Inc. The Company's operations are subject to complex and stringent environmental, health, safety and other governmental laws and regulations.
» More Articles for AFFX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: PXLW, NGPC, MS, CHMT, AFFX Aug 15 2011 
Affymetrix Inc. (AFFX) CFO Timothy C Barabe buys 5,000 Shares Nov 19 2010 
Affymetrix Inc. (AFFX) CFO Timothy C Barabe buys 10,000 Shares Aug 24 2010 
Weekly CFO Buys Highlight: AspenBio Pharma, Solarwinds, Affymetrix, Cascade Financial Corp., Bank of Jul 31 2010 
Weekly CFO Buys Highlight: Ocean BioChem, Solarwinds Inc., PDL BioPharma, Autobytel Inc., Affymetrix May 08 2010 
Affymetrix Inc. Reports Operating Results (10-Q) May 06 2010 
Weekly CFO Buys Highlight: Ocean BioChem, Affymetrix, Richardson Electronics, First Defiance Financi May 02 2010 
Affymetrix Reports Fourth Quarter and Fiscal Year 2008 Results Jan 28 2009 
Affymetrix to Host Conference Call on January 28, 2009 to Announce Fourth Quarter and Fiscal 2008 Re Jan 27 2009 
Weekly CEO Buys Highlight: ScheringPlough Corp., Novellus Systems Inc., SeaBright Insurance Holdings May 01 2008 


More From Other Websites
Why Affymetrix (AFFX) Could Be an Impressive Growth Stock Aug 11 2014
AFFYMETRIX INC Financials Aug 09 2014
AFFYMETRIX INC Files SEC form 10-Q, Quarterly Report Aug 04 2014
Affymetrix Down despite Q2 Earnings and Revenues Beat Aug 04 2014
Affymetrix Earnings Call scheduled for 5:00 pm ET today Jul 31 2014
AFFYMETRIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Jul 31 2014
4:01 pm Affymetrix beats by $0.04, beats on revs Jul 31 2014
Affymetrix Reports Second Quarter 2014 Operating Results Jul 31 2014
Q2 2014 Affymetrix Earnings Release - After Market Close Jul 31 2014
Affymetrix to Report Second Quarter 2014 Operating Results on Thursday July 31, 2014 Jul 07 2014
Zacks Rank #1 Additions for Thursday Jul 03 2014
Earnings Estimates Moving Higher for Affymetrix (AFFX): Time to Buy? Jun 26 2014
AFFYMETRIX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Jun 25 2014
Zacks' Bull Of The Day: Affymetrix Jun 25 2014
Affymetrix, ZAIS Financial and Capstead Mortgage highlighted as Zacks Bull and Bear of the Day Jun 25 2014
Bull of the Day: Affymetrix (AFFX) Jun 25 2014
A Few Medical Research Stocks Break Out, Others Basing Jun 09 2014
Affymetrix, BioDiscovery Launch Cancer Research Software Jun 06 2014
Affymetrix (AFFX) Stock: Moving Average Crossover Alert Jun 06 2014
AFFYMETRIX INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events Jun 05 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide